BLCO
Bausch + Lomb Corporation NYSE Listed May 6, 2022$15.94
Mkt Cap $5.7B
52w Low $10.99
62.5% of range
52w High $18.91
50d MA $16.53
200d MA $15.93
P/E (TTM)
-16.0x
EV/EBITDA
19.3x
P/B
0.9x
Debt/Equity
0.8x
ROE
-3.4%
P/FCF
-91.6x
RSI (14)
—
ATR (14)
—
Beta
0.65
50d MA
$16.53
200d MA
$15.93
Avg Volume
477.5K
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye. The Ophthalmic Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of eye conditions, such as glaucoma, ocular hypertension, and retinal diseases; and contact lenses for therapeutic use. The Surgical segment provides tools and technologies for the treatment of cataracts, and vitreous and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices. The company was founded in 1853 and is headquartered in Vaughan, Canada.
520 Applewood Crescent · Vaughan, ON L4K 4B4 · CA
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 29, 2026 | BMO | 0.06 | 0.08 | +33.3% | 15.72 | +2.2% | -2.4% | +1.1% | +3.8% | +3.7% | +1.8% | — |
| Feb 18, 2026 | BMO | 0.35 | 0.32 | -8.6% | 17.73 | -5.5% | -0.3% | -0.5% | +1.2% | +1.5% | +4.0% | — |
| Oct 29, 2025 | BMO | 0.16 | 0.18 | +12.5% | 15.20 | +5.2% | +1.8% | -0.4% | -1.7% | +0.3% | -1.3% | — |
| Jul 30, 2025 | BMO | 0.06 | 0.07 | +16.7% | 14.65 | +2.9% | -6.4% | -7.0% | -7.8% | -6.3% | -1.4% | — |
| Apr 30, 2025 | BMO | 0.03 | -0.07 | -333.3% | 13.72 | -14.7% | -15.7% | -15.5% | -16.2% | -17.1% | -20.6% | — |
| Feb 19, 2025 | BMO | 0.24 | 0.25 | +4.2% | 16.35 | -0.6% | -0.3% | -2.8% | -3.7% | -3.3% | -2.3% | — |
| Oct 30, 2024 | BMO | 0.16 | 0.17 | +6.2% | 20.76 | -0.5% | -1.5% | -2.3% | -1.2% | -4.3% | -4.6% | — |
| Jul 31, 2024 | BMO | 0.13 | 0.13 | +0.0% | 16.87 | -1.8% | +2.1% | -0.1% | -3.2% | -8.7% | -5.5% | — |
| May 1, 2024 | BMO | 0.09 | 0.07 | -22.2% | 14.54 | -3.1% | -5.5% | -4.7% | -6.5% | -0.7% | +2.5% | — |
| Feb 21, 2024 | BMO | 0.17 | 0.24 | +41.2% | 14.59 | +9.3% | +13.8% | +18.7% | +20.6% | +15.7% | +17.3% | — |
| Nov 1, 2023 | BMO | 0.18 | 0.22 | +22.2% | 16.14 | +1.1% | +2.4% | +4.6% | +6.2% | +2.9% | +3.2% | — |
| Aug 2, 2023 | BMO | 0.16 | 0.18 | +12.5% | 19.35 | -0.9% | -2.3% | -2.5% | -3.7% | -3.4% | -3.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30 | Evercore ISI | Maintains | In Line → In Line | — | $15.34 | $15.32 | -0.1% | +3.7% | +6.3% | +6.3% | +4.3% | +4.3% |
| Apr 6 | Evercore ISI | Maintains | In Line → In Line | — | $16.49 | $16.54 | +0.3% | -0.9% | -3.5% | +0.3% | -0.1% | +0.0% |
| Feb 23 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.94 | $18.06 | +0.7% | +0.3% | +2.8% | +3.7% | +3.1% | +2.0% |
| Feb 19 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $17.67 | $17.62 | -0.3% | -0.1% | +1.5% | +1.8% | +4.4% | +5.3% |
| Feb 19 | Citigroup | Maintains | Buy → Buy | — | $17.67 | $17.62 | -0.3% | -0.1% | +1.5% | +1.8% | +4.4% | +5.3% |
| Feb 19 | Stifel | Maintains | Hold → Hold | — | $17.67 | $17.62 | -0.3% | -0.1% | +1.5% | +1.8% | +4.4% | +5.3% |
| Feb 19 | Barclays | Maintains | Equal Weight → Equal Weight | — | $17.67 | $17.62 | -0.3% | -0.1% | +1.5% | +1.8% | +4.4% | +5.3% |
| Feb 17 | Stifel | Maintains | Hold → Hold | — | $17.03 | $17.07 | +0.2% | +4.1% | +3.8% | +3.6% | +5.3% | +5.6% |
| Jan 5 | Evercore ISI | Downgrade | Outperform → In Line | — | $16.58 | $16.22 | -2.2% | +1.3% | +3.3% | +4.9% | +4.3% | +3.8% |
| Dec 2 | Morgan Stanley | Upgrade | Equal Weight → Overweight | — | $16.56 | $17.63 | +6.5% | +3.0% | +2.4% | +1.5% | +1.6% | +0.0% |
| Nov 14 | RBC Capital | Maintains | Outperform → Outperform | — | $15.69 | $15.58 | -0.7% | -0.6% | -4.4% | -3.8% | -6.8% | -7.2% |
| Nov 14 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $15.69 | $15.58 | -0.7% | -0.6% | -4.4% | -3.8% | -6.8% | -7.2% |
| Oct 31 | Barclays | Maintains | Equal Weight → Equal Weight | — | $15.14 | $15.21 | +0.5% | -1.3% | +0.7% | -0.9% | +3.9% | +2.6% |
| Oct 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.14 | $15.21 | +0.5% | -1.3% | +0.7% | -0.9% | +3.9% | +2.6% |
| Oct 30 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $15.47 | $15.31 | -1.0% | -2.1% | -3.4% | -1.4% | -3.0% | +1.7% |
| Oct 30 | Raymond James | Maintains | Outperform → Outperform | — | $15.47 | $15.31 | -1.0% | -2.1% | -3.4% | -1.4% | -3.0% | +1.7% |
| Oct 30 | JP Morgan | Maintains | Neutral → Neutral | — | $15.47 | $15.31 | -1.0% | -2.1% | -3.4% | -1.4% | -3.0% | +1.7% |
| Oct 30 | Evercore ISI | Maintains | Outperform → Outperform | — | $15.47 | $15.31 | -1.0% | -2.1% | -3.4% | -1.4% | -3.0% | +1.7% |
| Oct 7 | Evercore ISI | Maintains | Outperform → Outperform | — | $14.89 | $14.81 | -0.5% | -1.5% | -1.2% | -3.2% | -3.8% | -0.1% |
| Aug 1 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $13.63 | $13.58 | -0.4% | -1.0% | +0.7% | +5.9% | +3.5% | +1.2% |
| Jul 31 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $13.71 | $13.55 | -1.2% | -0.6% | -1.5% | +0.1% | +5.3% | +2.9% |
| Jul 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $13.71 | $13.55 | -1.2% | -0.6% | -1.5% | +0.1% | +5.3% | +2.9% |
| Jul 9 | Citigroup | Maintains | Neutral → Neutral | — | $14.00 | $13.92 | -0.6% | +0.4% | +1.4% | -0.9% | -2.3% | -2.1% |
| Jul 8 | Evercore ISI | Maintains | Outperform → Outperform | — | $13.81 | $13.85 | +0.3% | +1.4% | +1.7% | +2.8% | +0.5% | -0.9% |
| Jun 9 | Barclays | Maintains | Equal Weight → Equal Weight | — | $11.70 | $11.65 | -0.4% | +2.4% | +7.5% | +6.9% | +6.3% | +5.4% |
| May 6 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $11.37 | $11.19 | -1.6% | -4.1% | +0.3% | +1.1% | -0.9% | +4.6% |
| May 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $11.59 | $11.65 | +0.5% | -0.8% | -1.9% | -6.0% | -1.6% | -0.8% |
| May 1 | Evercore ISI | Maintains | Outperform → Outperform | — | $11.56 | $11.61 | +0.4% | +0.3% | -0.5% | -1.6% | -5.7% | -1.4% |
| May 1 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $11.56 | $11.61 | +0.4% | +0.3% | -0.5% | -1.6% | -5.7% | -1.4% |
| May 1 | Citigroup | Maintains | Neutral → Neutral | — | $11.56 | $11.61 | +0.4% | +0.3% | -0.5% | -1.6% | -5.7% | -1.4% |
| Apr 24 | Needham | Maintains | Hold → Hold | — | $12.74 | $13.37 | +4.9% | +9.0% | +7.8% | +7.2% | +7.7% | -9.3% |
| Apr 4 | RBC Capital | Maintains | Outperform → Outperform | — | $12.99 | $12.79 | -1.5% | -6.8% | -8.6% | -15.3% | -3.5% | -12.9% |
| Apr 3 | Stifel | Maintains | Hold → Hold | — | $14.35 | $13.90 | -3.1% | -9.5% | -15.6% | -17.3% | -23.3% | -12.7% |
| Mar 28 | Wells Fargo | Downgrade | Overweight → Equal Weight | — | $15.00 | $14.66 | -2.3% | -5.8% | -3.3% | -6.0% | -4.3% | -13.4% |
| Feb 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.89 | $15.77 | -0.8% | -0.9% | -0.5% | +0.5% | -0.2% | -0.6% |
| Feb 20 | BofA Securities | Maintains | Underperform → Underperform | — | $16.30 | $16.04 | -1.6% | -2.5% | -3.4% | -3.0% | -2.0% | -2.7% |
| Feb 20 | RBC Capital | Maintains | Outperform → Outperform | — | $16.30 | $16.04 | -1.6% | -2.5% | -3.4% | -3.0% | -2.0% | -2.7% |
| Feb 20 | Needham | Maintains | Hold → Hold | — | $16.30 | $16.04 | -1.6% | -2.5% | -3.4% | -3.0% | -2.0% | -2.7% |
| Feb 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $16.41 | $16.35 | -0.4% | -0.4% | -0.7% | -3.2% | -4.0% | -3.7% |
| Jan 29 | Stifel | Maintains | Hold → Hold | — | $17.41 | $17.06 | -2.0% | +2.7% | +1.4% | -0.3% | +0.2% | +0.5% |
| Jan 29 | RBC Capital | Maintains | Outperform → Outperform | — | $17.41 | $17.06 | -2.0% | +2.7% | +1.4% | -0.3% | +0.2% | +0.5% |
| Jan 16 | Wells Fargo | Maintains | Overweight → Overweight | — | $17.27 | $17.04 | -1.3% | +1.0% | +0.5% | -0.5% | -1.2% | -2.4% |
| Dec 12 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.16 | $18.41 | +1.4% | +2.5% | +2.4% | +2.1% | +3.8% | +0.4% |
| Dec 11 | Citigroup | Downgrade | Buy → Neutral | — | $20.65 | $18.15 | -12.1% | -12.1% | -9.8% | -9.9% | -10.2% | -8.7% |
| Dec 2 | Morgan Stanley | Downgrade | Overweight → Equal Weight | — | $19.82 | $19.25 | -2.9% | -1.8% | -0.8% | -0.4% | +0.5% | +1.3% |
| Oct 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $20.44 | $20.49 | +0.2% | -0.8% | +0.3% | -2.8% | -3.1% | -3.0% |
| Oct 31 | Wells Fargo | Maintains | Overweight → Overweight | — | $20.44 | $20.49 | +0.2% | -0.8% | +0.3% | -2.8% | -3.1% | -3.0% |
| Oct 31 | Citigroup | Maintains | Buy → Buy | — | $20.44 | $20.49 | +0.2% | -0.8% | +0.3% | -2.8% | -3.1% | -3.0% |
| Oct 22 | RBC Capital | Maintains | Outperform → Outperform | — | $20.68 | $20.45 | -1.1% | -1.6% | -2.9% | -2.4% | -1.1% | -1.5% |
| Oct 15 | Evercore ISI | Upgrade | In Line → Outperform | — | $20.87 | $21.33 | +2.2% | -0.6% | -0.5% | +0.3% | -1.1% | -0.9% |
No insider trades available.
8-K
Bausch + Lomb Corporation -- 8-K Filing
Bausch + Lomb delivered strong quarterly growth driven by dry eye treatments like MIEBO and XIIDRA, plus premium contact lenses and intraocular lenses, supporting management's strategy of sustainable expansion.
Apr 29
8-K
Unknown — 8-K Filing
Blco's phase 1/2 data showing 97% of patients eliminated eye drop dependency suggests strong commercial potential for its implantable device, making the $172.5M IPO attractive for investors seeking ophthalmology innovation exposure.
Mar 26
8-K
Bausch + Lomb Corporation -- 8-K Filing
Bausch + Lomb demonstrated improved operational efficiency in Q4 with EBITDA margin expansion, signaling management confidence in executing its three-year growth strategy.
Feb 18
Data updated apr 24, 2026 9:57pm
· Source: massive.com